Supply of abatacept (ORENCIA) products by Bristol-Myers Squibb Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and quality of therapeutic goods in Australia, thereby addressing the need for a robust framework to ensure the safety, efficacy, and quality of such products. The Act was introduced to fill the legislative gap that existed in the regulation of therapeutic goods, providing a comprehensive legal structure for the oversight of these products. Enacted by the Parliament of Australia, the Act aims to protect public health by ensuring that only therapeutic goods that meet the required standards are supplied within the country. On July 16, 2013, the delegate of the Secretary of the Department of Health and Ageing exercised powers under the Act to provide specific consent for the supply of certain products that did not conform to the stipulated labelling requirements, subject to certain conditions to mitigate any potential risks to public health.

Scope and Application

The Therapeutic Goods Act 1989 (the Act) applies to the regulation of therapeutic goods in Australia, encompassing products such as medicines, medical devices, and blood and blood components. The Act is administered by the Therapeutic Goods Administration (TGA), a part of the Department of Health, and its authority extends to the entire Commonwealth of Australia. The Act's application covers both the import and supply of therapeutic goods within Australia, ensuring that these products meet safety, quality, and efficacy standards. The Act applies to a wide range of entities, including manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as to the goods themselves. The Act's scope includes the regulation of advertising and labelling of therapeutic goods, and it provides mechanisms for the approval, monitoring, and enforcement of compliance with therapeutic goods standards. There are specific exclusions and exemptions, such as for certain classes of goods that may be regulated under other legislation, and for research and clinical trial purposes under particular conditions. The Act can extend its application through subordinate instruments such as Therapeutic Goods Orders (TGOs) and Therapeutic Goods Regulations, which provide detailed specifications and requirements for particular therapeutic goods or classes of goods.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") provides for the regulation of therapeutic goods in Australia. Specifically, sections 14 and 14A of the Act concern the supply of therapeutic goods that do not conform with specified standards or requirements. Section 14 allows for the supply of such goods under certain conditions, while Section 14A requires the delegate of the Secretary of the Department of Health and Ageing to provide consent for such supply. In this case, the delegate has given consent for the supply of two abatacept products (ORENCIA) 250 mg powder for IV infusion vial and 125 mg single dose syringe subcutaneous injection flange extender by Bristol-Myers Squibb Australia Pty Ltd, subject to certain conditions. The obligations imposed by the Act on the parties involved include strict compliance with the conditions set out in the consent. For instance, Bristol-Myers Squibb Australia Pty Ltd must ensure that the products supplied do not deviate from the specified standards beyond the allowed exceptions. Specifically, they must retain a mail redirection service from the address on the label to the current sponsor address, and ensure no other changes are made to the products. These conditions are designed to maintain the integrity and safety of the therapeutic goods supplied. Failure to comply with the conditions of the consent may result in significant legal consequences. Under the Act, there are potential offences and penalties for breaches of the conditions. Although the specific penalties are not detailed in the Gazette, the general provisions of the Act outline that offences can lead to substantial fines and, in severe cases, imprisonment. Additionally, any breach of the conditions could result in civil liability for any harm caused by the non-conforming therapeutic goods. This underscores the importance of adhering to the stipulated conditions to avoid legal repercussions.